Martinez de Tejada Guillermo, Heinbockel Lena, Ferrer-Espada Raquel, Heine Holger, Alexander Christian, Bárcena-Varela Sergio, Goldmann Torsten, Correa Wilmar, Wiesmüller Karl-Heinz, Gisch Nicolas, Sánchez-Gómez Susana, Fukuoka Satoshi, Schürholz Tobias, Gutsmann Thomas, Brandenburg Klaus
Universidad de Navarra, Dept. de Microbiología y Parasitología, Irunlarrea 1, 31008 Pamplona, Spain.
Divisions of Biophysics, Research Center Borstel, Leibniz-Center for Medicine and Biosciences, Parkallee 1-40, 23845 Borstel, Germany.
Sci Rep. 2015 Sep 22;5:14292. doi: 10.1038/srep14292.
Sepsis, a life-threatening syndrome with increasing incidence worldwide, is triggered by an overwhelming inflammation induced by microbial toxins released into the bloodstream during infection. A well-known sepsis-inducing factor is the membrane constituent of Gram-negative bacteria, lipopolysaccharide (LPS), signalling via Toll-like receptor-4. Although sepsis is caused in more than 50% cases by Gram-positive and mycoplasma cells, the causative compounds are still poorly described. In contradicting investigations lipoproteins/-peptides (LP), lipoteichoic acids (LTA), and peptidoglycans (PGN), were made responsible for eliciting this pathology. Here, we used human mononuclear cells from healthy donors to determine the cytokine-inducing activity of various LPs from different bacterial origin, synthetic and natural, and compared their activity with that of natural LTA and PGN. We demonstrate that LP are the most potent non-LPS pro-inflammatory toxins of the bacterial cell walls, signalling via Toll-like receptor-2, not only in vitro, but also when inoculated into mice: A synthetic LP caused sepsis-related pathological symptoms in a dose-response manner. Additionally, these mice produced pro-inflammatory cytokines characteristic of a septic reaction. Importantly, the recently designed polypeptide Aspidasept(®) which has been proven to efficiently neutralize LPS in vivo, inhibited cytokines induced by the various non-LPS compounds protecting animals from the pro-inflammatory activity of synthetic LP.
脓毒症是一种在全球发病率不断上升的危及生命的综合征,它由感染期间释放到血液中的微生物毒素引发的过度炎症所触发。一种著名的脓毒症诱导因子是革兰氏阴性菌的膜成分脂多糖(LPS),它通过Toll样受体4发出信号。尽管超过50%的脓毒症病例是由革兰氏阳性菌和支原体细胞引起的,但致病化合物仍描述甚少。在相互矛盾的研究中,脂蛋白/肽(LP)、脂磷壁酸(LTA)和肽聚糖(PGN)被认为是引发这种病理状况的原因。在此,我们使用来自健康供体的人单核细胞来测定来自不同细菌来源(合成的和天然的)的各种LP的细胞因子诱导活性,并将它们的活性与天然LTA和PGN的活性进行比较。我们证明,LP是细菌细胞壁中最有效的非LPS促炎毒素,通过Toll样受体2发出信号,不仅在体外如此,而且接种到小鼠体内时也是如此:一种合成LP以剂量反应方式引发了与脓毒症相关的病理症状。此外,这些小鼠产生了脓毒症反应特有的促炎细胞因子。重要的是,最近设计的多肽Aspidasept(®)已被证明能在体内有效中和LPS,它抑制了由各种非LPS化合物诱导的细胞因子,保护动物免受合成LP的促炎活性影响。